Introduction
============

Crohn\'s disease is a chronic gastrointestinal disease mainly related to eating habits and autoimmune function, and clinical statistical analysis found that the incidence of this disease in China is increasing ([@b1-etm-0-0-6559]--[@b3-etm-0-0-6559]). Crohn\'s disease can cause systemic symptoms, such as lesions in mouth, eyes, skin, and gastrointestinal tract. Occurrence site of Crohn\'s disease is mainly the gastrointestinal tract, and highest incidence is found in ileum and colon ([@b4-etm-0-0-6559],[@b5-etm-0-0-6559]). Clinically, Crohn\'s disease is mainly treated with antibiotics, immunosuppressive agents and other drugs ([@b6-etm-0-0-6559]--[@b9-etm-0-0-6559]). Antibiotics may cause the development of intestinal flora resistance, and the immunosuppressive agents are not affordable for most patients. At present, probiotics and glucocorticoid are incresingly widely used to treat this disease ([@b2-etm-0-0-6559],[@b10-etm-0-0-6559],[@b11-etm-0-0-6559]). In this study, probiotics combined with glucocorticoid therapy was used to treat Crohn\'s disease. The clinical treatment effects were observed and compared.

Patients and methods
====================

### Materials

A total of 83 patients with Crohn\'s disease were selected from March 2015 to December 2017 in PLA Army General Hospital (Beijing, China). Patients were randomly divided into the control group and treatment group. The treatment group included 23 males and 20 females, with an average age of 43.43±5.43 years and an average disease duration of 2.12±1.09 years. The control group included 20 males and 20 females, with an average age of 48.43±5.43 years and an average disease duration of 2.01±1.02 years. The healthy group included 19 males and 21 females, with an average age of 44.76±4.99 years. There was no significant difference between the three groups in general information such as age, sex and disease duration.

Inclusion criteria were: patients who met the criteria for 'diagnosis and treatment of inflammatory bowel disease'; patients who were not suffering from heart, liver or other vital organ injuries; patients without mental diseases; patients who could cooperate with the researchers.

Exclusion criteria were: patients who were allergic to probiotics and glucocorticoids; patients who were pregnant or in lactation; patients with other intestinal diseases.

The study was approved by the Ethics Committee of PLA Army General Hospital (Beijing, China). Patients who participated in this study, signed an informed consent and had complete clinical data. Signed informed consents were obtained from the patients or guardians.

### Methods

Patients in the control group were treated with routine treatment of oral sulfasalazine at a dose of 1 g each time, 4 times per day. Besides oral sulfasalazine, patients in the treatment group were treated with probiotics combined with glucocorticoids. Probiotics: *Bifidobacterium Lactobacillus* triple tablets, at the dose of 4 × 500 mg per time, 2 times per day. Glucocorticoids: prednisone, at the initial dose of 0.75--1.0 mg/kg/day and gradually stopped in3-4 months.

### Efficacy evaluation and observation indicators

The levels of inflammatory cytokines C-reactive protein (CRP, TNF-α and IL-10) were measured before and after treatment. The inflammatory cytokines were determined by using ELISA kit (Beyotime, Shanghai, China).

Determination of intestinal flora: fresh feces was collected from patients and healthy individuals, and yeast, *peptococcus, lactobacilli* and *enterococci* were isolated, cultured and detected.

Clinical efficacy: recovery, clinical symptoms and signs disappeared after treatment, stool routine examination was negative, microscopic ulcer was healed, mucosal recovery was observed; markedly effective, clinical symptoms and signs disappeared after treatment, stool routine examination was negative, microscopic ulcer was mostly healed; effective, clinical symptoms and signs disappeared after treatment, stool routine examination was negative and mild inflammation was observed by microscopic examination; ineffective, clinical symptoms and signs were not improved or aggregated. Total effective rate = (recovered cases + apparent effective cases + effective cases)/total number ×100%.

### Statistical analysis

Statistical software SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data. Enumeration data were expressed as mean ± standard deviation. Enumeration data were recorded as a number. Comparison between multiple groups was done using One-way ANOVA test followed by a post hoc test (Least Significant Difference). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Comparison of general clinical data between the two groups of patients

There were 23 males and 20 females in the treatment group, including 19 patients with ileocolic, 17 patients with ileum, 7 patients with colon, and 21 patients with stenosis and 15 patients with penetration type and 7 patients with non-penetration type. There were 20 males and 20 females in the control group, including 15 patients with ileocolic, 16 patients with ileum, 9 patients with colon, and 19 patients with stenosis and 14 patients with penetration type and 7 patients with non-penetration type. There was no significant difference in sex, lesion location and type of lesion between the two groups ([Table I](#tI-etm-0-0-6559){ref-type="table"}).

### Comparison of inflammatory cytokines between the two groups of patients

Before treatment, the levels of CRP, TNF-α and IL-10 in the treatment group were 13.39±0.93 ng/ml, 2.45±0.21 ng/ml and 14.35±1.67 pg/ml, respectively. No significant differences in the levels of CRP, TNF-α and IL-10 were found between the two groups. After treatment, the levels of these inflammatory factors in both groups were significantly decreased, and the levels of the inflammatory factors in the treatment group were significantly lower than those in the control group (P\<0.05). The levels of the inflammatory factors in the treatment group reached the levels of that in the control group ([Table II](#tII-etm-0-0-6559){ref-type="table"}).

### Comparison of intestinal flora between the groups of patients and healthy individuals

Before treatment, no significant differences in number of yeast, *enterococci, lactobacilli* and *peptococcus* intestinal flora were found between the two groups. After treatment, the levels of yeast, *enterococci* and *peptococcus* of the groups of patients were significantly decreased, while the level of *lactobacillus* was significantly increased in both groups, and the changes were more significant in the treatment group than those in the control group. After treatment, the number of intestinal flora in the treatment group reached that of the healthy individuals ([Table III](#tIII-etm-0-0-6559){ref-type="table"}).

### Comparison of clinical efficacy of the two groups of patients

In the treatment group, 15 patients recovered, 21 were markedly effective, 6 were effective, and the total effective rate was 97.6%. In the control group, 8 patients recovered, 15 were markedly effective, and 11 patients were effective, and the total effective rate was 85.3%. Therapeutic efficiency of the the treatment group was significantly higher than that of the control group (P\<0.05) ([Table IV](#tIV-etm-0-0-6559){ref-type="table"}).

### Comparison of incidence of infection between the two groups of patients

In the treatment group, 8 patients developed infectious abdominal distension and diarrhea, 9 patients developed abdominal abscess, 4 patients developed pulmonary infection, 1 patient developed sepsis, and the overall incidence was 51.1%. In the control group, 12 patients developed infectious abdominal distension and diarrhea, 11 patients developed abdominal abscess, 8 patients developed pulmonary infection, 5 patients developed sepsis, and the overall incidence was 92.7%. The infection rate of the control group was significantly higher than that of the treatment group (P\<0.05) ([Table V](#tV-etm-0-0-6559){ref-type="table"}).

Discussion
==========

Crohn\'s disease is an inflammatory bowel disease that can cause serious complications of infection. Antibiotics are generally used in the treatment of Crohn\'s disease, while long-term use of antibiotics may lead to the development of resistance, which in turn may affect treatment outcomes ([@b12-etm-0-0-6559],[@b13-etm-0-0-6559]). In this study, probiotics combined with glucocorticoid was used to treat Crohn\'s disease, so as to explore the clinical efficacy of this treatment effect and the impact on intestinal flora.

Treatment with probiotics is safe for the intestine, and can provide nutrients for the intestine, improve the level of intestinal flora and maintain the balance of flora ([@b14-etm-0-0-6559],[@b15-etm-0-0-6559]). Glucocorticoids can rapidly diffuse into the cytoplasm after entering the body and bind to hormone receptors in cells. Glucocorticoid can bind to corresponding reactants and activate the expression of relevant genes to exert anti-inflammatory effects ([@b16-etm-0-0-6559],[@b17-etm-0-0-6559]).

TNF-α as the major inflammatory and immune function factor in the body is mainly produced by activated monocytes and megakaryocytes. When inflammation occurs, the level of TNF-α significantly increases, thereby inducing the secretion of a variety of inflammatory factors and adhesion molecules. IL-10 as an important inflammatory factor in Crohn\'s disease is mainly produced by activated monocytes. IL-10 inhibits the secretion of inflammatory mediators by monocytes, and has a strong anti-inflammatory effect. In Crohn\'s disease, intestinal flora is imbalanced mainly due to the proliferation of yeast. At the same time, the numbers of *enterococcus* and *peptococcus* were significantly increased, while the number of *lactobacillus* was decreased, seriously affecting the intestinal digestive function ([@b18-etm-0-0-6559],[@b19-etm-0-0-6559]).

This study showed that the effective rate of the treatment group was significantly higher than that of the control group (97.6 vs. 85.3%), indicating the use of probiotics combined with glucocorticoid treatment can improve treatment effect and effectively alleviate clinical symptoms. After treatment, the levels of inflammatory factors in the treatment group were significantly lower than those in the control group. After entering the human body, probiotics can improve intestinal damage, protect intestinal wall permeability, thereby reducing the levels of proinflammatory substances such as inflammatory cytokines and endotoxin in lamina propria, thereby inhibiting inflammation. Glucocorticoids reduce the secretion of arachidonic acid, which is a proinflammatory precursor in the body, thereby inhibiting the production and secretion of inflammatory cytokines. After treatment, intestinal flora was improved, the levels of yeast, *enterococci* and *peptococcus* were significantly decreased, and the level of *lactobacillus* was increased. The improvement is more significant in the treatment group than that in the control group, indicating the probiotics combined with glucocorticoid treatment can play a better role than conventional methods in protecting intestinal flora. Results also showed that probiotics combined with glucocorticoid treatment can reduce the incidence of infection, abdominal distension, diarrhea and other side effects.

In conclusion, the use of probiotics combined with glucocorticoid in the treatment of Crohn\'s disease can improve clinical efficacy, reduce infection rate, improve the protective effect of intestinal flora, and effectively control the production and secretion of inflammatory cytokines. Therefore, this treatment should be popularized in clinical practice.
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###### 

Comparison of general clinical data between two groups of patients (n).

                   Sex   Lesion localization   Lesion type                      
  ----------- ---- ----- --------------------- ------------- ---- --- ---- ---- ---
  Treatment   43   23    20                    19            17   7   21   15   7
  Control     40   20    20                    15            16   9   19   14   7

###### 

Comparison of inflammatory cytokines between two groups of patients (mean ±SD).

  Groups                Time-points                                             CRP (ng/ml)   TNF-α (ng/ml)   IL-10 (pg/ml)
  --------------------- ------------------------------------------------------- ------------- --------------- ---------------
  Treatment             Before treatment                                        13.39±0.93    2.45±0.21       14.35±1.67
                        After treatment                                         7.21±0.89     0.72±0.08       10.23±1.86
                        P value^[a](#tfn1-etm-0-0-6559){ref-type="table-fn"}^   \<0.001       \<0.001         \<0.001
  Control               Before treatment                                        13.51±1.21    2.61±0.21       14.98±1.45
                        After treatment                                         10.56±1.09    1.72±0.11       13.25±1.75
                        P value^[b](#tfn2-etm-0-0-6559){ref-type="table-fn"}^   \<0.001       \<0.001         \<0.001
                        P value^[c](#tfn3-etm-0-0-6559){ref-type="table-fn"}^   \<0.001       \<0.001         \<0.001
  Healthy individuals                                                           6.23±0.65     0.69±0.08       9.81±0.99
                        P value^[d](#tfn4-etm-0-0-6559){ref-type="table-fn"}^   \<0.001       \<0.001         \<0.001

Comparison between before and after treatment in the treatment group

Comparison between before and after treatment in the control group

Comparison between after treatment in the control group and after treatment in the treatment group

Comparison between the healthy group and after treatment in the treatment group.

###### 

Comparison of intestinal flora between two groups of patients and healthy individuals (mean ±SD).

  Groups                Time-points        Yeast                                                                                                  *Enterococci*                                                                                          *Lactobacilli*                                                                                         *Peptococcus*
  --------------------- ------------------ ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  Treatment             Before treatment   2.23±0.21                                                                                              6.73±0.65                                                                                              5.63±0.53                                                                                              6.23±0.63
                        After treatment    1.03±0.01^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"}^                                                5.32±0.43^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"}^                                                8.31±0.82^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"}^                                                3.89±0.32^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"}^
  Control               Before treatment   2.42±0.21                                                                                              6.79±0.62                                                                                              5.73±0.51                                                                                              6.29±0.61
                        After treatment    1.59±0.12^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"},[b](#tfn6-etm-0-0-6559){ref-type="table-fn"}^   6.21±0.60^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"},[b](#tfn6-etm-0-0-6559){ref-type="table-fn"}^   6.93±0.62^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"},[b](#tfn6-etm-0-0-6559){ref-type="table-fn"}^   5.79±0.59^[a](#tfn5-etm-0-0-6559){ref-type="table-fn"},[b](#tfn6-etm-0-0-6559){ref-type="table-fn"}^
  Healthy individuals                      0.92±0.08                                                                                              5.24±0.52                                                                                              8.23±0.80                                                                                              3.93±0.34

P\<0.05, compared with the pretreatment level

P\<0.05, compared with the treatment group.

###### 

Comparison of clinical efficacy of two groups of patients (n).

  Groups      Cases   Recovery   Markedly effective   Effective   Ineffective   Total effective rate (%)
  ----------- ------- ---------- -------------------- ----------- ------------- ---------------------------------------------------------
  Treatment   43      15         21                     6         1             42 (97.6)
  Control     40        8        15                   11          6             34 (85.3)^[a](#tfn7-etm-0-0-6559){ref-type="table-fn"}^

P\<0.05, compared with the treatment group.

###### 

Comparison of incidence of infection between two groups of patients (n).

  Groups      Cases   Infectious abdominal distension and diarrhea   Abdominal abscess   Pulmonary infection   Sepsis   Incidence (%)
  ----------- ------- ---------------------------------------------- ------------------- --------------------- -------- ---------------------------------------------------------
  Treatment   43      8                                              9                   4                     1        22 (51.1)
  Control     40      12                                             11                  8                     5        36 (92.7)^[a](#tfn8-etm-0-0-6559){ref-type="table-fn"}^

P\<0.05, compared with the treatment group.
